Analyst Consensus ?
ConsensusBuy35 ratings
Bullish2262.9%
Neutral1131.4%
Bearish25.7%
1 unmapped firm rating excluded from the percentages.
Corteva, Inc. · CTVA · FY2026 Q2 · Calendar Q3 2026
Corteva raises 2026 outlook as licensing and products support growth
Corteva's raised outlook and product and licensing momentum strengthen the operating case, while Latin America pricing and farmer-margin pressure remain key tests.
Reported After market closeNYSEBasic Materials
$53.69B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.30
Consensus $2.24
EPS surprise
+2.7%
Reported versus consensus
Reported revenue
$6.38B
Consensus $6.60B
Revenue surprise
-3.3%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-11.9%
Event window
SPY move
+0.7%
Same window
Abnormal move
-12.6%
Stock minus SPY
Volume
3.3×
Versus trailing sessions
Subsequent drift
+6.6%
Up to 20 sessions
CTVASPY benchmark
Ask FN2 about CTVA FY2026 Q2
Transcript, numbers and history already loaded
Why did CTVA fall 11.9% after beating EPS estimates in FY2026 Q2?What changed in CTVA's guidance and outlook in FY2026 Q2?Give me the bull and bear case for CTVA after FY2026 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Management raised full-year operating EBITDA and EPS outlooks after a strong first half. The planned separation remains on track for October 1, with a smaller-than-expected separation headwind.
Guidance delta
Raised full-year operating EBITDA guidance to $4.1-$4.3 billion and EPS guidance to $3.60-$3.80.
Key takeaways
- First-half results exceeded expectations, with double-digit EBITDA growth and margin expansion.
- New product launches, licensing revenue and productivity initiatives are supporting growth.
- The separation into two public companies is on track for October 1, with limited expected cost impact.
- Latin America pricing pressure and tight farmer margins remain important execution risks.
Management priorities
- Execute the October 1 separation and launch Vylor as a standalone seed and genetics company.
- Continue new-product launches, including the pipeline of seven new actives.
- Expand licensing, productivity initiatives and the nature-based and biological portfolio.
Follow CTVA with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$80.34Previous close
$53Low
$78.58Average
$103High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Sep 23, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Argus Research | Buy | Buy | Maintain | Sep 18, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Sep 17, 2026 |
| UBS | Neutral | Neutral | Maintain | Sep 16, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Sep 16, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Sep 16, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 3, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Jul 23, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 20, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 14, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jun 11, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | May 28, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Apr 21, 2026 |
| Keybanc | Overweight | Downgrade | Oct 3, 2025 | |
| Jefferies | Buy | Buy | Maintain | Jun 6, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Jun 12, 2024 |
| OTR Global | Negative | Mixed | Downgrade | Jun 7, 2024 |
| Canaccord Genuity | Buy | Buy | Maintain | May 3, 2024 |
| Loop Capital | Buy | Hold | Upgrade | Feb 12, 2024 |
| Exane BNP Paribas | Neutral | Underperform | Upgrade | Feb 2, 2024 |
| Roth MKM | Buy | Buy | Maintain | Jan 29, 2024 |
| Berenberg | Hold | Buy | Downgrade | Nov 27, 2023 |
| Fermium Research | Outperform | Outperform | Maintain | Oct 30, 2023 |
| Goldman Sachs | Neutral | Neutral | Maintain | Oct 24, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 4, 2023 |
| Redburn Partners | Neutral | Buy | Downgrade | Jul 25, 2023 |
| Vertical Research | Buy | Hold | Upgrade | May 22, 2023 |
| Roth Capital | Buy | Buy | Maintain | Oct 8, 2021 |
| Monness, Crespi, Hardt | Neutral | Sell | Upgrade | Aug 9, 2021 |
| Redburn | Neutral | Buy | Downgrade | Jan 21, 2021 |
| Susquehanna | Positive | Neutral | Upgrade | Mar 31, 2020 |
| Edward Jones | Buy | Hold | Upgrade | Mar 19, 2020 |
| Bernstein | Outperform | Market Perform | Upgrade | Jan 23, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | Oct 11, 2019 |
| Citi | Buy | Neutral | Upgrade | Aug 19, 2019 |
| Monness Crespi Hardt | Sell | Sell | Maintain | Jul 17, 2019 |
| Nomura | Neutral | Neutral | Maintain | Jun 10, 2019 |
Named analyst price targets
Upside is calculated against the persisted previous close $80.34. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BMO Capital | Joel Jackson | $95 | $83.11 | +18.2% | Sep 16, 2026 |
| New Street | Analyst unavailable | $95 | $83.39 | +18.2% | Sep 16, 2026 |
| UBS | Analyst unavailable | $90 | $83.39 | +12.0% | Sep 16, 2026 |
| Deutsche Bank | David Begleiter | $101 | $77.75 | +25.7% | Aug 3, 2026 |
| BMO Capital | Joel Jackson | $100 | $78.71 | +24.5% | Aug 3, 2026 |
| RBC Capital | Arun Viswanathan | $103 | $86.78 | +28.2% | Jul 21, 2026 |
| Mizuho Securities | Analyst unavailable | $97 | $85.72 | +20.7% | Jul 14, 2026 |
| Mizuho Securities | Analyst unavailable | $96 | $85.25 | +19.5% | Jul 2, 2026 |
| Barclays | Benjamin Theurer | $91 | $74.46 | +13.3% | Jun 11, 2026 |
| UBS | Joshua Spector | $86 | $75.86 | +7.0% | Jun 9, 2026 |
| Morgan Stanley | Vincent Andrews | $95 | $79.89 | +18.2% | May 28, 2026 |
| RBC Capital | Arun Viswanathan | $95 | $78.62 | +18.2% | Apr 24, 2026 |
| Wells Fargo | Analyst unavailable | $90 | $80.29 | +12.0% | Apr 21, 2026 |
| UBS | Analyst unavailable | $88 | $83.56 | +9.5% | Apr 9, 2026 |
| Mizuho Securities | Analyst unavailable | $82 | $75.03 | +2.1% | Feb 17, 2026 |
| UBS | Joshua Spector | $80 | $72.6 | -0.4% | Feb 9, 2026 |
| RBC Capital | Analyst unavailable | $89 | $72.99 | +10.8% | Feb 5, 2026 |
| Oppenheimer | Analyst unavailable | $86 | $72.99 | +7.0% | Feb 5, 2026 |
| Goldman Sachs | Analyst unavailable | $88 | $75.12 | +9.5% | Feb 5, 2026 |
| Wells Fargo | Analyst unavailable | $85 | $75.12 | +5.8% | Feb 5, 2026 |
| Oppenheimer | Analyst unavailable | $78 | $72.63 | -2.9% | Jan 27, 2026 |
| Mizuho Securities | Edlain Rodriguez | $80 | $70.5 | -0.4% | Jan 16, 2026 |
| Oppenheimer | Analyst unavailable | $76 | $63.38 | -5.4% | Nov 7, 2025 |
| UBS | Analyst unavailable | $81 | $61.53 | +0.8% | Oct 30, 2025 |
| Oppenheimer | Analyst unavailable | $75 | $62.79 | -6.6% | Oct 22, 2025 |
| Wells Fargo | Analyst unavailable | $80 | $61.91 | -0.4% | Oct 16, 2025 |
| Mizuho Securities | Analyst unavailable | $78 | $65.61 | -2.9% | Oct 8, 2025 |
| UBS | Analyst unavailable | $85 | $64.56 | +5.8% | Oct 6, 2025 |
| Morgan Stanley | Analyst unavailable | $84 | $74.29 | +4.6% | Sep 15, 2025 |
| BMO Capital | Analyst unavailable | $86 | $74.29 | +7.0% | Sep 15, 2025 |
| Oppenheimer | Kristen Owen | $87 | $72.09 | +8.3% | Jul 15, 2025 |
| KeyBanc | Aleksey Yefremov | $71 | $60.29 | -11.6% | Apr 14, 2025 |
| KeyBanc | Aleksey Yefremov | $69 | $60.76 | -14.1% | Nov 21, 2024 |
| Citigroup | Patrick Cunningham | $68 | $59.12 | -15.4% | Oct 23, 2024 |
| Bank of America Securities | Steve Byrne | $67 | $57.3 | -16.6% | Oct 16, 2024 |
| Mizuho Securities | John Roberts | $61 | $57.85 | -24.1% | Sep 25, 2024 |
| Oppenheimer | Kriten Owen | $69 | $57.04 | -14.1% | Sep 17, 2024 |
| KeyBanc | Aleksey Yefremov | $62 | $53 | -22.8% | Aug 2, 2024 |
| Mizuho Securities | John Roberts | $60 | $51.89 | -25.3% | Jun 18, 2024 |
| Wolfe Research | Chris Parkinson | $68 | $51.9 | -15.4% | Jun 11, 2024 |
| Deutsche Bank | David Begleiter | $65 | $57.03 | -19.1% | May 6, 2024 |
| RBC Capital | Arun Viswanathan | $64 | $57.16 | -20.3% | May 6, 2024 |
| Canaccord Genuity | Bobby Burleson | $65 | $56.98 | -19.1% | May 3, 2024 |
| BMO Capital | Joel Jackson | $67 | $56.98 | -16.6% | May 3, 2024 |
| Jefferies | Laurence Alexander | $67 | $57 | -16.6% | Mar 28, 2024 |
| Loop Capital Markets | Christopher Kapsch | $65 | $55.04 | -19.1% | Feb 12, 2024 |
| BNP Paribas | Laurent Favre | $53 | $53.04 | -34.0% | Feb 2, 2024 |
| Wells Fargo | Analyst unavailable | $77 | $61.54 | -4.2% | Feb 3, 2023 |
| Citigroup | Analyst unavailable | $74 | $61.68 | -7.9% | Feb 3, 2023 |
| Morgan Stanley | Analyst unavailable | $80 | $62.12 | -0.4% | Jan 11, 2023 |
| Barclays | Analyst unavailable | $75 | $65.35 | -6.6% | Nov 17, 2022 |
| UBS | Analyst unavailable | $73 | $66.72 | -9.1% | Nov 16, 2022 |
| Credit Suisse | John Roberts | $68 | $51.26 | -15.4% | Jul 14, 2022 |
| Barclays | Benjamin Theurer | $71 | $53.22 | -11.6% | Jun 20, 2022 |
| Deutsche Bank | David Begleiter | $72 | $62.04 | -10.4% | Jun 6, 2022 |
| Argus Research | Bill Selesky | $69 | $60.91 | -14.1% | May 24, 2022 |
| Mizuho Securities | Analyst unavailable | $67 | $57.99 | -16.6% | Apr 29, 2022 |
| Roth Capital | Brian White | $56 | $50.25 | -30.3% | Feb 4, 2022 |
| Barclays | Duffy Fischer | $54 | $47.33 | -32.8% | Nov 5, 2021 |
| Deutsche Bank | David Begleiter | $55 | $44.79 | -31.5% | Aug 8, 2021 |
| Argus Research | Bill Selesky | $54 | $45.82 | -32.8% | May 17, 2021 |
| Bank of America Securities | Steve Byrne | $42 | $46.45 | -47.7% | May 10, 2021 |
Track every rating change on CTVA the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCorteva, Inc. operates in the agriculture business. The company operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics. This segment also provides digital solutions that assist farmer decision-making with a view to optimize product selection, and maximize yield and profitability.…
Historical context
All CTVA earningsBasic Materials peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| HMY Harmony Gold Mining Company Limited | FY2026 Q4 · Calendar Q3 2026 | 0.0% | -6.2% | Harmony Gold posts record FY2026 while Eva Copper risks remain |
Latest beats and misses
Who reports nextBeat on EPS
- AZOFY2026 Q4 · September 22, 2026+3.6% EPS+3.3% move
- FPSFY2026 Q4 · September 15, 2026+4.3% EPS+9.5% move
- TCOMFY2026 Q2 · September 15, 2026+22.3% EPS+3.0% move
- KRFY2026 Q2 · September 11, 2026+2.8% EPS+2.7% move
- ADBEFY2026 Q3 · September 10, 2026+0.8% EPS+1.4% move
- ORCLFY2027 Q1 · September 10, 2026+10.3% EPS-1.7% move
Get the CTVA recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-31T15:08:27.974488+00:00
- FN2 earnings calendar · 2026-09-04T01:23:15.205020+00:00
- Polygon adjusted daily market bars · 2026-09-23T07:00:55.764329+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-23T07:00:55.761480+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-23. For educational purposes only; not investment advice.